Find the stocks the market is misreading

A stock analysis platform that turns isolated figures into meaningful investment insights using the Financial X-Ray Framework.

Data. Context. Conclusions.

How The Inside Analyst works

A 50-second overview of the research process and Financial X-Ray framework.

Why investors use the Financial X-Ray

Instead of juggling dozens of metrics and conflicting signals, the Financial X-Ray highlights where a company's strengths, risks and valuation stand today.

No longer...
Your benefit
× Confusion about which metrics really matter
A structured diagnostic view that highlights where strength and pressure sit
× Manually weighing growth, valuation and financial health
An integrated rating that balances trade-offs for you
× Relying on news and commentary
Diagnostic signals based on financial structure
× Collecting data from multiple sources
One integrated financial framework
× Time-consuming financial research
Instant, on-demand structural analysis

The Financial X-Ray

Most dashboards overwhelm. Most analyst narratives simplify. Most stock tips skip financial correlations.

Business quality does not live in one metric –
it emerges from how financial health, capital allocation, growth and valuation interact.

The Financial X-Ray makes those interactions visible – clearly and consistently.

→ Learn more about us

What to expect

Quickly understand whether a company is fundamentally attractive

See where a business is strong – and where risks may be hiding

Cut through earnings noise and conflicting financial metrics

Compare companies using one consistent rating framework

Make investment decisions with more structure and less guesswork

Build your portfolio and roast it!

See what recent examples reveal

The Inside Analyst selects stocks where fundamentals and value drift apart. Top stories are published on Substack.

Favicon The Inside Analyst showing dark blue background and light blue small squares that are connected.

Top stories

Inside the Portfolio #1 Stocks That Set the Foundation

These stocks contribute to the portfolio's balance and outperformance. The Financial X-Ray identifies businesses whose economics remain remarkably difficult to break. Since launching the Financial X-Ray Selection Portfolio in June 2023, one question has appeared more often than almost any other.Which companies form the basis of the portfolio and survive the rigorous quality assessments year after year? The Financial X-Ray Selection has outperformed the MSCI World since inception while maintaining a focused portfolio of 38 holdings.I don’t see that as proof that the framework is infallible, markets have a habit of humbling anyone who thinks they have found certainty.Instead, I see it as evidence that applying the same disciplined process to every business, month after month, can produce strong long-term outcomes. The conviction is simple: I don’t focus on intense trading or on chasing hype. Instead, the approach is to buy quality stocks at decent prices - or put differently, buy stocks with an X-Ray Score of “strong”.

JUL 9 · THE INSIDE ANALYST

Investing Doesn’t Have To Be Complicated

How a simple framework for buying financially strong businesses has outperformed the market since June 2023. Most investors believe better returns require more complexity. My experience suggests the opposite. I didn't start my career in finance because I wanted to predict stock prices. I wanted to understand how businesses create value, why some companies compound for decades while others slowly deteriorate, and whether those differences could be recognised before they became obvious to everyone else. Working as an equity analyst, I realised investors don't need more metrics. They need analysed conclusions they can base decisions on. And we must be able to understand how these conclusions were formed. If a company gets a “balanced” score on financial health, we must understand that this message doesn’t mean “nothing is happening”. It means that certain forces offset each other. Revenue may grow while debt explodes, strong cash generation may come with declining capital efficiency or improving margins do not convert into cashflow. As private investors we are left alone with isolated ratios, headlines and opinions. That gap is what eventually led me to build the Financial X-Ray. So instead of searching for the next winner and following headlines, reacting to earnings releases, comparing valuation multiples and constantly asking whether now is the right time to buy I’ve realised that investing is often made far more complicated than it needs to be. My simple conviction is that financially strong businesses outperform the market when bought at a sensible valuation level.Meaning: The businesses that create long-term wealth tend to share remarkably similar characteristics.

JUL 6 · THE INSIDE ANALYST

Eli Lilly Is Revolutionising Medicine – The Market May Already Expect Too Much

The Financial X-Ray reveals a dangerous mix of accelerating growth, rising leverage and collapsing cash generation.

JUL 13 · THE INSIDE ANALYST

Pick a stock and see structural strenghts and pain points

Most popular

ASML Is the AI Bottleneck – The Question Is How Much Is Already Priced In?

Combining long-term fundamental investing with the Financial X-Ray framework to separate market expectations from business reality. ASML sits at the center of the global semiconductor industry, dominates a critical technology stack and continues to deliver strong growth, profitability and cash generation. Every advanced semiconductor – whether used in AI servers, smartphones, autonomous vehicles or data centres – must first be manufactured using lithography equipment, making ASML a critical supplier to the global chip industry. ASML makes money in two ways: Net Bookings of hardware sales (i.e. lithography machines), and Installed Base Management (regular updates and software services). The former makes up about 2/3 of revenues, while the latter represents about 1/3 of total revenues. This is a crucial distinction because the former represents lumpy machinery sales, while the latter is a smooth, recurring revenue stream that turns over come rain or shine.

JUL 3 · THE INSIDE ANALYST

NVIDIA's Investment Case Rests on One Hidden Assumption.

The Financial X-Ray highlights an extraordinary business whose future still depends on maintaining exceptional conditions. NVIDIA’s financial transformation has been extraordinary.Revenue increased from just $11 billion in 2020 to more than $215 billion in 2026. EBITDA margins expanded from 31% to almost 67%, while free cash flow exceeded $95 billion. Return on invested capital climbed above 55% and the company now operates with virtually no net debt. Few companies have ever combined this level of growth, profitability and capital efficiency. Yet one characteristic has become even more pronounced. Nearly 90% of NVIDIA’s revenue now comes from its Data Center business. The company has become financially stronger than ever. It has also become more dependent on one extraordinary source of demand.

JUN 29 · THE INSIDE ANALYST

Favicon The Inside Analyst showing dark blue background and light blue small squares that are connected.

Archive

Merck – Why a “Defensive” Pharma Giant Produces Unpredictable Financials

When investors look at a company like Merck & Co., the expectation is usually a defensive business with predictable financial results. But the financial statements tell a more complicated story. At first glance, Merck’s financial profile looks solid.Revenue has expanded over time and the company continues to operate with strong profitability compared with most healthcare peers. Pharmaceutical products with strong market positions allow the business to generate attractive margins.However, the direction and stability of the underlying financial signals reveal a more nuanced picture.Revenue growth has slowed significantly in recent years. After a period of strong expansion driven by blockbuster products and pandemic-related demand, growth momentum has faded and results have become more dependent on the performance of a smaller number of key drugs.Profitability, while still high, has also shown unusual volatility. EBITDA margins have fluctuated significantly across periods as product cycles, research investments, and regulatory developments affect results.Free cash flow shows even greater instability. In some years the company generates substantial cash, while in others cash flow drops sharply or turns negative. These swings are partly driven by the nature of pharmaceutical development cycles, where research investments, product launches, and regulatory milestones create uneven financial outcomes.Capital efficiency follows a similar pattern. Returns on invested capital and equity remain strong on average but fluctuate significantly from year to year.The balance sheet itself remains relatively conservative. Leverage is moderate and the company continues to maintain financial flexibility. However, rising net debt in recent periods slightly offsets that stability.Taken together, the signals reveal an important interaction:The business remains fundamentally strong, but the financial outcomes are unusually volatile for a company perceived as defensive.This situation reflects a financial dynamic that does not fit into a framework and that is called Pharma Earnings Volatility – a financial pattern closest related to cash conversion fracture – when margins don’t translate into free cash flow (

MAR 16 · THE INSIDE ANALYST

ServiceNow – When Hypergrowth Becomes Healthy Growth

ServiceNow’s growth is slowing. That’s the headline investors focus on. But beneath the surface something unusual is happening. The business is getting stronger as the market becomes more cautious. ServiceNow remains one of the strongest enterprise software businesses in the market.Revenue growth is still exceptional by large-cap standards, remaining above 20 percent annually. Sustaining that level of expansion at scale reflects strong demand for workflow automation and enterprise digital transformation.At the same time, profitability has improved significantly. EBITDA margins have expanded as the platform scales and operating leverage materializes. The company increasingly benefits from the typical software dynamic: once core infrastructure and development costs are absorbed, incremental revenue becomes more profitable.Cash generation follows the same direction. Free cash flow has increased meaningfully, reinforcing the financial resilience of the business model.The balance sheet has strengthened as well. Net debt has declined, leaving the company with substantial financial flexibility.In other words, the economic quality of the business is improving.But the nature of growth is gradually changing.Revenue expansion is normalising from earlier hyper-growth levels as the company becomes larger. That shift is natural for a platform reaching greater scale, yet it often changes how investors interpret the story.Markets tend to focus heavily on the direction of growth, sometimes overlooking simultaneous improvements in profitability, capital efficiency, and cash generation.This creates a subtle tension: the fundamentals continue to strengthen even as the headline growth rate moderates.This situation reflects a recurring financial dynamic:The Growth Normalization Paradox.

MAR 12 · THE INSIDE ANALYST

Favicon The Inside Analyst showing dark blue background and light blue small squares that are connected.

The Inside Analyst

Want to receive top stories by email? Subscribe on Substack

↑ Back to top